Back to top
October 7, 2016
FDA Approves Lundbeck's New Drug
Treatments

The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (≤7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.

Read the press release

Related News

August 22, 2016
CURE Responds to DEA’s Decision on Marijuana Scheduling

This month the Drug Enforcement Administration (DEA) announced their decision to maintain marijuana as a Schedule I drug, despite petitions from...

July 26, 2016
The Fight to Improve Research Access to Cannabis Continues

Due to its incredible medicinal potential, we continue to believe that more research must be done on marijuana rich in cannabidiol (CBD).

May 20, 2016
Acorda Therapeutics, Inc. Announces Discontinuation of...

Acorda Therapeutics, Inc. announced May 20 it will discontinue development of PLUMIAZ™ (diazepam) Nasal Spray, an investigational therapy which...